Published in Biotech Business Week, November 7th, 2005
Currently there is no approved treatment for dry AMD. The proposed trial will have a 3-month efficacy endpoint and a 6-month safety endpoint and will include approximately 300 patients.
The PMA trial will assure TheraMac's safety and effectiveness for its intended use and that it will be manufactured in accordance with current good manufacturing practices. TheraMac received CE Marking in Europe in 2002.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.